Nektar Therapeutics Shares 52-Week REZOLVE-AA Data as Rezpeg Boosts SALT ≤20 Responses in Alopecia Areata



Nektar Therapeutics (NASDAQ:NKTR) presented 52-week top-line results from a 16-week blinded treatment extension of its Phase 2b REZOLVE-AA study evaluating rezpegaldesleukin (rezpeg) in adults with severe to very severe alopecia areata, emphasizing that additional dosing beyond 36 weeks increased th



Source link

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *